Evaluating the Effects of GLP-1 Receptor Agonists on Hepatic Function in Patients with Type 1 Diabetes (ELEGANT-T1D)
The goal of this study is to learn how certain medicines, like Ozempic and Mounjaro, affect the liver in people with type 1 diabetes. We are especially looking at a liver disease called MASLD (MASLD (metabolic dysfunction-associated steatotic liver disease), which happens when the liver builds up too much fat.
Why this Research Matters
You will complete questionnaires about your health and lifestyle, have blood drawn, and complete a liver ultrasound. You will participate in either a 1-time visit or be followed for up to 1 year (if intending to start a GLP-1 medication, like Ozempic or Mounjaro). Please reach out to Scott Maclean at scott.2.maclean@cuanschutz.edu or 303-724-8348 or complete the following survey: https://redcap.link/elegant_t1d_prescreen.
Who can Participate
Inclusion Criteria: • does not have diabetes OR • have type 1 diabetes for at least 15 years AND • either have never used a GLP-1 medication or used a GLP-1 medication for at least 1 year • no history of liver disease • 18-80 years old Exclusion Criteria: • Currently pregnant • History of bariatric surgery
Study ID
Protocol Number: 25-2469
Meet the Team
Scott Maclean
Principal Investigator